Green Valley Announces NMPA Approval Of Oligomannate For Mild ...
SHANGHAI, Nov. 4, 2019 /PRNewswire-AsiaNet/ -- -Oligomannate, A New Oral Treatment For Mild To Moderate Alzheimer's Disease -The Only Approved Novel AD Treatment Globally Since 2003Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products...
Authors: LATEST ASIANET NEWS RELEASES